Sir John is Chairman of the Newcastle upon Tyne Hospitals NHS Foundation Trust, Professor of Clinical Genetics at Newcastle University, led the regional NHS Genetics Service for 20 years and helped to create the International Centre for Life.

Jonathan is the co-founder of QuantuMDx, former Chief Scientific Officer and inventor of many of its proprietary technologies. Jonathan has a specialist interest in antimicrobial resistance (AMR) and was a diagnostics advisor for the O’Neill Review. He was awarded European CTO of the Year in 2015.

James is the managing partner and co-founder of Vita Spring IVD Fund, who participated as the institutional investor, and support the management team in fund raising and strategic development. Prior to his investment career, he worked as an investment banker for seven years and was an Executive Director in Goldman Sachs.

Jonathan is a highly experienced professional with more than 23 years of expertise in the Life Science sector. After earning his degree in Genetics from Newcastle University and completing his PhD in Immunogenetics, Jonathan began his professional journey as a Project Manager for Cels. In this role, he was responsible for promoting their business, developing collaborations, and generating funding. He later joined Bionow, a UK Life Science Membership Organisation, where he continued to excel. With over 10 years of experience with QuantuMDx, Jonathan has proven skills in commercial planning, strategic account management, and developing and executing go-to-market strategies. His successful commercial plans have secured £10m of grant income for QuantuMDx and played a key role in a strategic partnership with a large Asian Pacific Company. Throughout his career, Jonathan has consistently demonstrated his ability to drive growth, generate revenue, and establish valuable partnerships in the Life Science industry.

Martin has over 25 years’ experience of working with large global companies. He previously set up and managed Excalibur Medicines Ltd, he sits on the Board of Interrad Medical and is a Partnership Board Member of the Liverpool Life Sciences Accelerator.

Justine has been with QuantuMDx Group for almost eight years and in that time has gathered a wealth of experience of working in the life sciences sector. Justine joined as Financial Controller in 2015, and was promoted to VP Finance in 2018. In that time, Justine has developed a high-performing financial team, introduced and enhanced the managment reporting within the Company, transitioned the statutory reporting to IFRS from UK GAAP, maximised R&D tax credit subsidies to the business, managed the implementation of the ERP system and been instrumental in all of the Company's recent fund-raising activities. Justine qualified as an ACA with the "Big Four" accountancy firm, EY and left two years post-qualification. Since then, Justine has worked across financial departments in both local SMEs and large Global Companies, her most recent post prior to joining QuantuMDx was Financial Reporting Manager at FTSE 100 Company, The Sage Group plc.

Paul has a very diverse entrepreneurial and executive leadership background in healthcare services, life sciences and medical device industries. He has held roles as Founder, CEO and Board Member. Paul has successfully led teams from ideation through to exit. His experience includes 10+ start-ups, capital formation in excess of $50M+, distressed turnarounds, roll-ups, 20+ M&A transaction with cumulative value of $100M+ and multi-site operations. Industry sectors include EMS/ambulance, advanced life support emergency medical services, physical therapy and rehabilitation services, international nurse recruiting and staffing, breast cancer risk screening, multiplex point of care molecular DX testing and endovascular catheter drug delivery devices. Ventures range from pre-revenue to $250M revenue. Paul has served on a number of industry and company boards of directors including servicing as Chairman of the Board of Life Sciences TN-USA 2020-22. He frequently provides mentorship to start-ups and early stage company entrepreneurs. Paul was an original Board Member of QuantuMDx Group 2008-2017.

Andy is a specialist in global operations and manufacturing with over 24 years' experience in the medical device and life sciences sector. During a 13-year tenure with Thermofisher, he successfully launched over 40 products in the UK and German facilities. The remaining time at Thermofisher was spent in the life sciences division leading a 24x7 manufacturing facility as site Operations Manager, with a turnover of $38M and 156 employees, outputting over 10 million PCR consumables per year. Andy led all operational activities across the site, initiated and managed the continuous improvement program, which led to his site being awarded best in class. The site expanded by 25%, establishing an ISO-13485 manufacturing facility and supplying customers such as Roche. Andy gained start-up experience with Vivacta Ltd where he was Director of Manufacturing during the lead up to the acquisition by Novartis. He then progressed to Global Head of Manufacturing Operations and during his 5-year tenure, Andy fulfilled Novartis' high standards leading and establishing in house manufacturing of Niji cassette consumables in the UK and successfully achieving ISO-13485 certification. Andy also participated in assessing potential new technology acquisitions.

Robin is a specialist in biosensor technologies with over 18 years’ experience working in academia and industry. Robin has in-depth experience of molecular biology and surface chemistry and currently leads our project management team.

Jennie joined QuantuMDx in September 2021. Prior to joining, she worked as a Sales Director for Oxford Immunotec, a $74 million-revenue global high growth diagnostics company from 2014-2021, leading the NW European sales teams and achieving double digit growth in a competitive specialised market, Oxford was acquired by Perkin Elmer in 2019. Prior to this, Jennie was employed in sales leadership roles and has over 30 years' experience within the pharmaceutical and diagnostic health care industry. She worked for J&J, where she headed up a team of Healthcare Development Executives, working to seek partnerships in diabetes in the primary care environment, and Roche, where she managed a team of Healthcare Managers operating across the oncology and haematology portfolio.